What did Piper Sandler change for TEVA on March 04, 2026?

Piper Sandler maintained an **Overweight** rating on Teva (TEVA) and raised its price target to **$41** on March 04, 2026, as reported by StreetInsider.

What does a maintained Overweight mean for TEVA investors?

A maintained **Overweight** means the analyst expects TEVA to outperform peers over 12 months; investors may view it as a buy-leaning signal but should confirm with valuation and risk checks.

How should I use the TEVA price target of $41?

Use the **$41** price target as a valuation reference point. Compare it to current trading levels, earnings outlook, and debt metrics to assess realistic upside before adjusting positions.

How authoritative is this TEVA analyst rating update?

It reflects Piper Sandler’s view; helpful for sentiment but not definitive. The TEVA analyst rating from one firm should be balanced with consensus, company filings, and independent analysis.

Analyst Ratings

Piper Sandler Maintains Overweight on Teva Pharmaceutical Ltd (TEVA) Mar 2026

ByHuzaifa Zahoor March 5, 2026

Piper Sandler maintained an Overweight rating on Teva Pharmaceutical Industries Limited (TEVA) and raised its price target to $41 on March 04, 2026, a clear signal of confidence from a major healthcare desk. The TEVA analyst rating note emphasizes stronger specialty sales and pipeline progress, and StreetInsider published the firm’s commentary the same day. This action keeps Teva in a buy-leaning category for investors while signaling a valuation gap versus the new target. Investors should weigh the updated Piper Sandler view against TEVA’s market cap of $37,725,301,800 and recent price movement of 1.91% ($0.62)